A safety review of topical bovine thrombin-induced generation of antibodies to bovine proteins

Clinical Therapeutics

Volumn 31, Issue 4, 2009, Pages 679-691

  Ofosu, Frederick A ^a,b   Crean, Sheila ^c   Reynolds, Matthew W ^c  

^a MCMASTER UNIVERSITY   (Canada)

^b CANADIAN BLOOD SERVICES   (Canada)

^c UNITED BIOSOURCE CORPORATION   (United States)

Author keywords

adverse events; immunogenicity; recombinant proteins; surgical hemostasis; topical thrombin

Indexed keywords

ANTICOAGULANT AGENT; BLOOD CLOTTING FACTOR 10; BLOOD CLOTTING FACTOR 5; BLOOD CLOTTING FACTOR 7; BLOOD CLOTTING FACTOR 9; COLLAGEN; FIBRASTAT; FIBRINOGEN; FLOSEAL; GELFOAM; HEPARIN; PROTEIN ANTIBODY; PROTHROMBIN; RECOMBINANT ENZYME; RECOMBINANT HUMAN THROMBIN; THROMBIN; THROMBIN ANTIBODY; THROMBIN JMI; THROMBOSTAT; UNCLASSIFIED DRUG;

ABSCESS; ANEMIA; ANTIBODY PRODUCTION; ANTIBODY TITER; ARTERY THROMBOSIS; BLEEDING; BLOOD TRANSFUSION REACTION; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; CONSTIPATION; DEEP VEIN THROMBOSIS; DRUG EXPOSURE; DRUG FATALITY; DRUG FEVER; DRUG HYPERSENSITIVITY; DRUG SAFETY; EPISTAXIS; GASTROINTESTINAL HEMORRHAGE; GRAFT STENOSIS; HEMOSTASIS; HUMAN; HYPERCOAGULABILITY; HYPOKALEMIA; IMMUNOGENICITY; INSOMNIA; LUNG EMBOLISM; MEDIASTINITIS; MEDLINE; MESENTERIC THROMBOSIS; NAUSEA; PAIN; PERICARDITIS; PERIOPERATIVE PERIOD; PERIPHERAL EDEMA; POSTOPERATIVE HEMORRHAGE; POSTOPERATIVE INFECTION; RECURRENT DISEASE; REVIEW; RHINOCONJUNCTIVITIS; RISK; SEROMA; SIDE EFFECT; SKIN MANIFESTATION; STENOSIS; STROKE; SURGICAL PATIENT; THROMBOCYTE COUNT; THROMBOPHLEBITIS; THROMBOSIS; TRANSITIONAL BLINDNESS; UNSPECIFIED SIDE EFFECT; VENOUS THROMBOEMBOLISM; VOMITING; WOUND COMPLICATION; WOUND DRAINAGE; WOUND INFECTION;

ADMINISTRATION, TOPICAL; ANIMALS; ANTIBODY FORMATION; CATTLE; HEMOSTASIS, SURGICAL; HEMOSTATICS; HUMANS; PERIOPERATIVE CARE; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RECOMBINANT PROTEINS; THROMBIN;

EID: 65549130489     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/j.clinthera.2009.04.021     Document Type: Review

References (73)

1. Jackson M.R., MacPhee M.J., Drohan W.N., and Alving B.M. Fibrin sealant: Current and potential clinical applications. Blood Coagul Fibrinolysis 7 (1996) 737-746
2. Alving B.M., Weinstein M.J., Finlayson J.S., et al. Fibrin sealant: Summary of a conference on characteristics and clinical uses. Transfusion 35 (1995) 783-790
3. von Oppell U.O., and Zilla P. Tissue adhesives in cardiovascular surgery. J Long Term Eff Med Implants 8 (1998) 87-101
4. Dorion R.P., Hamati H.F., Landis B., et al. Risk and clinical significance of developing antibodies induced by topical thrombin preparations. Arch Pathol Lab Med 122 (1998) 887-894
5. Lundblad R.L., Bradshaw R.A., Gabriel D., et al. A review of the therapeutic uses of thrombin. Thromb Haemost 91 (2004) 851-860
6. Ortel T.L., Charles L.A., Keller F.G., et al. Topical thrombin and acquired coagulation factor inhibitors: Clinical spectrum and laboratory diagnosis. Am J Hematol 45 (1994) 128-135
7. Lawson J.H. The clinical use and immunologic impact of thrombin in surgery. Semin Thromb Hemost 32 Suppl 1 (2006) 98-110
8. Cmolik B.L., Spero J.A., Magovern G.J., and Clark R.E. Redo cardiac surgery: Late bleeding complications from topical thrombin-induced factor V deficiency. J Thorac Cardiovasc Surg 105 (1993) 222-227 discussion
9. Cmolik B.L., Spero J.A., Magovern G.J., and Clark R.E. Redo cardiac surgery: Late bleeding complications from topical thrombin-induced factor V deficiency. J Thorac Cardiovasc Surg 105 (1993) 227-228
10. Diez-Martin J., Sikkink R.A., Gilchrist G.S., et al. Development of anti-bovine thrombin antibodies following neurosurgical procedures. Br J Haematol 74 (1990) 369-370
11. Flaherty M.J., Henderson R., and Wener M.H. Iatrogenic immunization with bovine thrombin: A mechanism for prolonged thrombin times after surgery. Ann Intern Med 111 (1989) 631-634
12. Zehnder J.L., and Leung L.L. Development of antibodies to thrombin and factor V with recurrent bleeding in a patient exposed to topical bovine thrombin. Blood 76 (1990) 2011-2016
13. Cruickshank M.K., Black J., and Wall W. Development of a factor V and thrombin inhibitor following partial hepatic resection and the use of topical thrombin concentrate. Clin Lab Haematol 16 (1994) 187-190
14. Israels S.J., and Israels E.D. Development of antibodies to bovine and human factor V in two children after exposure to topical bovine thrombin. Am J Pediatr Hematol Oncol 16 (1994) 249-254
15. Muntean W., Zenz W., Finding K., et al. Inhibitor to factor V after exposure to fibrin sealant during cardiac surgery in a two-year-old child. Acta Paediatr 83 (1994) 84-87
16. Chouhan V.D., De La Cadena R.A., Nagaswami C., et al. Simultaneous occurrence of human antibodies directed against fibrinogen, thrombin, and factor V following exposure to bovine thrombin: Effects on blood coagulation, protein C activation and platelet function. Thromb Haemost 77 (1997) 343-349
17. Ortel T.L., Mercer M.C., Thames E.H., et al. Immunologic impact and clinical outcomes after surgical exposure to bovine thrombin. Ann Surg 233 (2001) 88-96
18. Christie R.J., Carrington L., and Alving B. Postoperative bleeding induced by topical bovine thrombin: Report of two cases. Surgery 121 (1997) 708-710
19. Kajitani M., Ozdemir A., Aguinaga M., et al. Severe hemor-rhagic complication due to acquired factor V inhibitor after single exposure to bovine thrombin product. J Card Surg 15 (2000) 378-382
20. Poynton A.R., Nelson M.C., McCance S.E., et al. Bovine thrombin induces an acquired coagulopathy in sensitized patients undergoing revision spinal surgery: A report of two cases. Spine 28 (2003) E221-E223
21. Winterbottom N., Kuo J.N., Nguyen K., et al. Antigenic responses to bovine thrombin exposure during surgery: A prospective study of 309 patients. J Appl Res Clin Exp Ther 2 (2002) 1-12
22. Schoenecker J.G., Hauck R.K., Mercer M.C., et al. Exposure to topical bovine thrombin during surgery elicits a response against the xenogeneic carbohydrate galactose alpha 1-3 galactose. J Clin Immunol 20 (2000) 434-444
23. Nelson P.A., Powers J.N., Estridge T.D., et al. Serological analysis of patients treated with a new surgical hemostat containing bovine proteins and autologous plasma. J Biomed Mater Res 58 (2001) 710-719
24. Hermeling S., Crommelin D.J., Schellekens H., and Jiskoot W. Structure-immunogenicity relationships of therapeutic proteins. Pharm Res 21 (2004) 897-903
25. Wadhwa M., Bird C., Dilger P., et al. Strategies for detection, measurement and characterization of unwanted antibodies induced by therapeutic biologicals. J Immunol Methods 278 (2003) 1-17
26. Astermark J. Overview of inhibitors. Semin Hematol 43 Suppl4 (2006) S3-S7
27. Rapaport S.I., Zivelin A., Minow R.A., et al. Clinical significance of antibodies to bovine and human thrombin and factor V after surgical use of bovine thrombin. Am J Clin Pathol 97 (1992) 84-91
28. Schoenecker J.G., Johnson R.K., Fields R.C., et al. Relative purity of thrombin-based hemostatic agents used in surgery. J Am Coll Surg 197 (2003) 580-590
29. Carroll J.F., Moskowitz K.A., Edwards N.M., et al. Immunologic assessment of patients treated with bovine fibrin as a hemostatic agent. Thromb Haemost 76 (1996) 925-931
30. Nilsson B., Horne III M.K., and Gralnick H.R. The carbohydrate of human thrombin: Structural analysis of gly-coprotein oligosaccharides by mass spectrometry. Arch Biochem Biophys 224 (1983) 127-133
31. Mizuochi T., Yamashita K., Fujikawa K., et al. The carbohydrate of bovine prothrombin. Occurrence of Gal beta 1 leads to 3GlcNAc grouping in asparagine-linked sugar chains. J Biol Chem 254 (1979) 6419-6425
32. Nelsestuen G.L., and Suttie J.W. The carbohydrate of bovine prothrombin. Partial structural determination demonstrating the presence of-galactose residues. J Biol Chem 247 (1972) 6096-6102
33. Galili U., Shohet S.B., Kobrin E., et al. Man, apes, and Old World monkeys differ from other mammals in the expression of alpha-galactosyl epitopes on nucleated cells. J Biol Chem 263 (1988) 17755-17762
34. Eckhardt A.E., Goldstein I.J., and Nelsestuen G.L. Bovine prothrombin does not contain alpha-D-galactopyra-nosyl groups. Arch Biochem Biophys 199 (1980) 635-636
35. Ahrens N., Pruss A., Kähne A., et al. Coexistence of autoantibodies and alloantibodies to red blood cells due to blood transfusion. Transfusion 47 (2007) 813-816
36. Garratty G. Autoantibodies induced by blood transfusion. Transfusion 44 (2004) 5-9
37. Mathiasen R.A., and Cruz R.M. Prospective, randomized, controlled clinical trial of a novel matrix hemostatic sealant in children undergoing adenoidectomy. Otolaryngol Head Neck Surg 131 (2004) 601-605
38. Chapman W.C., Singla N., Genyk Y., et al. A phase 3, randomized, doubleblind comparative study of the efficacy and safety of topical recombinant human thrombin and bovine thrombin in surgical hemostasis. J Am Coll Surg 205 (2007) 256-265
39. Weaver F.A., Lew W., Granke K., et al., for the Study Investigators. A comparison of recombinant human thrombin to bovine thrombin as a hemostatic ancillary in patients undergoing peripheral arterial bypass and arteriovenous graft procedures. J Vasc Surg 47 (2008) 1266-1273
40. Doria C., Fischer C.P., Wood C.G., et al. Phase 3, randomized, doubleblind study of plasma-derived human thrombin versus bovine thrombin in achieving hemostasis in patients undergoing surgery. Curr Med Res Opin 24 (2008) 785-794
41. Wai Y., Tsui V., Peng Z., et al. Anaphy-laxis from topical bovine thrombin (Thrombostat) during haemodialysis and evaluation of sensitization among a dialysis population. Clin Exp Allergy 33 (2003) 1730-1734
42. Sands J.J., Nudo S.A., Ashford R.G., et al. Antibodies to topical bovine thrombin correlate with access thrombosis. Am J Kidney Dis 35 (2000) 796-801
43. Su Z., Izumi T., Thames E.H., et al. Antiphospholipid antibodies after surgical exposure to topical bovine thrombin. J Lab Clin Med 139 (2002) 349-356
44. Adams J.D., Jones S., and Brost B.C. Development of antibodies to topical bovine thrombin after abdominal hysterectomy. A case report. J Reprod Med 46 (2001) 909-912
45. Berguer R., Staerkel R.L., Moore E.E., et al. Warning: Fatal reaction to the use of fibrin glue in deep hepatic wounds. Case reports. J Trauma 31 (1991) 408-411
46. Berruyer M., Amiral J., Ffrench P., et al. Immunization by bovine thrombin used with fibrin glue during cardiovascular operations. Development of thrombin and factor V inhibitors. J Thorac Cardiovasc Surg 105 (1993) 892-897
47. Caers J., Reekmans A., Jochmans K., et al. Factor V inhibitor after injection of human thrombin (tissucol) into a bleeding peptic ulcer. Endoscopy 35 (2003) 542-544
48. La Spada A.R., Skålhegg B.S., Henderson R., et al. Brief report: Fatal hemorrhage in a patient with an acquired inhibitor of human thrombin. N Engl J Med 333 (1995) 494-497
49. Rothenberg D.M., and Moy J.N. Anaphylac-tic reaction to topical bovine thrombin. Anesthesiology 78 (1993) 779-782
50. Sarfati M.R., Dilorenzo D.J., Kraiss L.W., and Galt S.W. Severe coagulopathy following intraoperative use of topical thrombin. Ann Vasc Surg 18 (2004) 349-351
51. Spero J.A. Bovine thrombin-induced inhibitor of factor V and bleeding risk in postoperative neurosurgical patients. Report of three cases. J Neurosurg 78 (1993) 817-820
52. Streiff M.B., and Ness P.M. Acquired FV inhibitors: A needless iatrogenic complication of bovine thrombin exposure. Transfusion 42 (2002) 18-26
53. Tarantino M.D., Ross M.P., Daniels T.M., and Nichols W.L. Modulation of an acquired coagulation factor V inhibitor with intravenous immune globulin. J Pediatr Hematol Oncol 19 (1997) 226-231
54. Zumberg M.S., Waples J.M., Kao K.J., and Lottenberg R. Management of a patient with a mechanical aortic valve and antibodies to both thrombin and factor V after repeat exposure to fibrin sealant. Am J Hematol 64 (2000) 59-63
55. Favaloro E.J., Posen J., Ramakrishna R., et al. Factor V inhibitors: Rare or not so uncommon? A multi-laboratory investigation. Blood Coagul Fibrinolysis 15 (2004) 637-647
56. Sands J.J., Nudo S.A., Moore K.D., and Ortel T.L. Antibodies to prothrombin, factor V, and beta2-glycoprotein I and vascular access thrombosis. ASAIO J 47 (2001) 507-510
57. Bänninger H., Hardegger T., Tobler A., et al. Fibrin glue in surgery: Frequent development of inhibitors of bovine thrombin and human factor V. Br J Haematol 85 (1993) 528-532
58. Muntean W., Zenz W., Edlinger G., and Beitzke A. Severe bleeding due to factor V inhibitor after repeated operations using fibrin sealant containing bovine thrombin. Thromb Haemost 77 (1997) 1223
59. Fastenau D.R., Wagenknecht D.R., Hormuth D.A., and McIntyre J.A. Left ventricular assist system recipients exposed to bovine thrombin preparations have a higher frequency of antiphospholipid antibodies than nonexposed recipients. ASAIO J 47 (2001) 537-540
60. Roberts H.R., and Cromartie R. Overview of inhibitors to factor VIII and IX. Prog Clin Biol Res 150 (1984) 1-18
61. Boekhorst J., Lari G.R., D'Oiron R., et al. Factor VIII genotype and inhibitor development in patients with haemophilia A: Highest risk in patients with splice site mutations. Haemophilia 14 (2008) 729-735
62. Goudemand J. Inhibitor development in haemophilia A: The role of von Willebrand factor/factor VIII concentrates. Haemophilia 13 Suppl 5 (2007) 47-51
63. Schwaab R., Brackmann H.H., Meyer C., et al. Haemophilia A: Mutation type determines risk of inhibitor formation. Thromb Haemost 74 (1995) 1402-1406
64. Kaveri S.V., Dasgupta S., and Andre S. Factor VIII inhibitors: Role of von Willebrand factor on the uptake of factor VIII by dendritic cells. Haemophilia 13 Suppl 5 (2007) 61-64
65. Kemball-Cook G., Tuddenham E.G., and Wacey A.I. The factor VIII Structure and Mutation Resource Site: HAMSTeRS version 4. Nucleic Acids Res 26 (1998) 216-219
66. Oldenburg J., El-Maarri O., and Schwaab R. Inhibitor development in correlation to factor VIII genotypes. Haemophilia 8 Suppl 2 (2002) 23-29
67. Basser R.L., O'Flaherty E., Green M., et al. Development of pancytopenia with neutralizing antibodies to thrombopoietin after multicycle chemotherapy supported by megakaryocyte growth and development factor. Blood 99 (2002) 2599-2602
68. Frost H. Antibody-mediated side effects of recombinant proteins. Toxicology 209 (2005) 155-160
69. Casadevall N., Nataf J., Viron B., et al. Pure red-cell aplasia and antieryth-ropoietin antibodies in patients treated with recombinant erythro poietin. N Engl J Med 346 (2002) 469-475
70. Van Haeften T.W. Clinical significance of insulin antibodies in insulin-treated diabetic patients. Diabetes Care 12 (1989) 641-648
71. Freund M., von Wussow P., Diedrich H., et al. Recombinant human interferon (IFN) alpha-2b in chronic myelogenous leukaemia: Dose dependency of response and frequency of neutralizing anti-interferon antibodies. Br J Haematol 72 (1989) 350-356
72. Steis R.G., Smith II J.W., Urba W.J., et al. Resistance to recombinant interferon alfa-2a in hairy-cell leukemia associated with neutralizing antiinterferon antibodies. N Engl J Med 318 (1988) 1409-1413
73. Giovannoni G., Munschauer III F.E., and Deisenhammer F. Neutralising antibodies to interferon beta during the treatment of multiple sclerosis. J Neurol Neurosurg Psychiatry 73 (2002) 465-469